

**Wednesday 13 November 2024: tours of Yposkesi and Généthon platform**

**Thursday 14 November 2024**

Time	Speaker	Topic	Type
9.00-9.30	Morning coffee		
9.30-9.40	Gilles Trystram, Genopole & Guillaume Douillet, Croda	Welcoming and introductions	Presentation
9.40-9.50	Laurence Lacroix-Orio, BD Director Genopole Carole Poutriquet, Country Sales Manager, Croda	UpScale: A new way to accelerate innovation @Genopole and @Croda	Presentation
9.50-10.10	Sarah Davidson, Technology Dev lead, Croda	Open Innovation Introduction	Presentation
10.10-10.20	Gavin Vuddamalay, Head of Scientific Affairs, MabDesign	French Biotherapies Market Overview	Presentation
10.20-10.50	Daniel Hamaoui, Président, SE-Therapeutics	Therapeutics delivery: Innovative intracellular delivery of gene editing	Presentation + Q/A
10.50-11.20	James Humphrey, R&T Specialist, Croda	Developing Super Refined ingredients to unlock the formulation and delivery of biologics.	Presentation + Q/A
11.20-11.40	Coffee break		
11.40-12.10	Dennis Christensen, Head of Global R&D Adjuvant Systems, Croda	Ensuring clinical availability of vaccine delivery systems, immunostimulators & combined adjuvant systems	Presentation + Q/A
12.10-12.40	Thierry Ziegler, co-founder, bYoRNA	Therapeutic mRNA production, current and future perspectives	Presentation + Q/A
12.40-13.40	Lunch break		
13.40-14.20	Rebecca Wood, Sector Sustainability Manager, Croda Paul-Henri Derrien, Dir. Dev. Industriel, France Biolead Alexandre Fontayne, CSO for Biologics, Unither Pharma Gwenaël Servant, VP business & Strategy, Abolis James Humphrey, R&T Specialist, Croda Dennis Christensen, Head of Global R&D adjuvant, Croda	Sustainability and Bioprocessing, are they compatible?	Interactive Round Table with Q/A
14.20-14.50	Soehnke Voss, Sales Dev Manager, Croda Kacee Sims, Head of insights and innovation, Croda (Kacee will be remote)	Lipid Nanoparticles: Beyond the classical approach	Presentation + Q/A
14.50-15.10	Coffee Break		
15.10-15.40	Manuel Vega, CEO, AGS-Therapeutics	MEVs (microalgae extracellular vesicles): a universal delivery system for therapeutics, vaccines, and gene therapies	Presentation + Q/A
15.40-16.20	Laurent Pépin, Consultant biotech Sam Collaudin, expert business strategy biotech Joël Cruzet, Serial entrepreneur biotech Dennis Christensen, Croda ; AdBio (panelist TBC)	Title TBC: Financial challenges and market access	Interactive Round Table with Q/A
16.20-16.35	Genopole + Croda	Thanks and Closing words	
16.35-18.00	Free time to network		